Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy

Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy

Background and Purpose: The tumor immune microenvironment (TIME) of breast cancer with positive human epidermal growth factor receptor 2 (HER2) is significantly related to the efficacy of trastuzumab, indicating the clinical potential of immunocheckpoint therapy combined with trastuzumab. This study...

Full description

Bibliographic Details
Main Author: YANG Wenxiao, GUO Linwei, LING Hong, HU Xin
Format: Article
Language:English
Published: Editorial Office of China Oncology 2023-05-01
Series:Zhongguo aizheng zazhi
Subjects:
|tumor immune microenvironment|trastuzumab|immunotherapy|human epidermal growth factor receptor 2-positive breast cancer|prediction model
Online Access:http://www.china-oncology.com/fileup/1007-3639/PDF/1686896442431-1211872650.pdf

Similar Items

Similar Items